DEPO DepoMed Inc.

Scott+Scott, Attorneys at Law, LLP Reminds Investors of October 17th Lead Plaintiff Deadline in Securities Class Action Against Depomed, Inc. (DEPO)

Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, reminds investors that October 17, 2017, is the deadline to move for lead plaintiff status in the securities class action pending against Depomed, Inc. (“Depomed” or the “Company”) (NASDAQ: DEPO). If you purchased Depomed shares between February 26, 2015 and August 7, 2017, you are encouraged to contact a Scott+Scott attorney at (844) 818-6982 for more information.

Depomed is a specialty pharmaceutical company focused on pain and other central nervous system conditions. The lawsuit alleges that, during the Class Period, Depomed made false and misleading statements regarding the Company’s questionable practices in connection with the sales and marketing of its opioid products.

On August 7, 2017, after the market closed, Depomed announced that it “recently received a request for information from the ranking minority member of the United States Senate Committee on Homeland Security and Governmental Affairs related to the promotion of opioids” as well as “subpoenas related to opioid sales and marketing from the Office of the Attorney General of Maryland and the United States Department of Justice.”

Following this news, Depomed’s stock price declined from a close of $9.23 on August 7th to close at $6.15 on August 8th – a drop of over 33%.

What You Can Do

If you purchased Depomed stock between February 26, 2015 and August 7, 2017 and you wish to discuss this lawsuit, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew at (844) 818-6982, or at [email protected]. The deadline to move for Lead Plaintiff status is October 17, 2017.

About Scott+Scott, Attorneys at Law, LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.

EN
12/10/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DepoMed Inc.

 PRESS RELEASE

Depomed Inc. Announces Corporate Name Change to Assertio Therapeutics,...

Depomed Inc. Announces Corporate Name Change to Assertio Therapeutics, Inc. Name Change Reflects Company’s Focus on Neurology, Orphan and Specialty Businesses LAKE FOREST, Ill., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT), a leading specialty pharmaceutical company committed to advancing patient care, has announced that its corporate name change from “Depomed, Inc.” to “Assertio Therapeutics, Inc.” became effective at 11:59 p.m. ET yesterday, August 14, 2018. In connection with the name change, the Company’s common stock will begin trading under a new ti...

 PRESS RELEASE

Depomed Announces Second-Quarter 2018 Financial Results

Depomed Announces Second-Quarter 2018 Financial Results -- Raises Full-Year Earnings and Adjusted EBITDA Guidance Range and Lowers Full-Year Net Sales Guidance Range for the Neurology Franchise -- -- Confirms Regulatory Plan to File for FDA Approval of Cosyntropin Depot by Year End -- -- Announces Agreement with PDL BioPharma to Monetize Royalty Stream; Company Received $20 Million in Cash -- -- Announces Planned Change in Company Name from Depomed to Assertio Therapeutics;Remains On-Track to Transition to New Corporate Headquarters in Lake Forest, Illinois -- LAKE FOREST, Ill., Aug. 0...

 PRESS RELEASE

Depomed to Report Second-Quarter 2018 Financial Results on Wednesday, ...

Depomed to Report Second-Quarter 2018 Financial Results on Wednesday, August 8, 2018 LAKE FOREST, Ill., July 09, 2018 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release second-quarter 2018 financial results on Wednesday, August 8, 2018, before the open of markets. Following the announcement, the Company will host a conference call beginning at 8:30 a.m. ET to discuss its results. Participants can access the live webcast from the Investor Relations section of Depomed's website at . Please access the website 15 minutes prior to the start of the call to dow...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch